Lipid profile and risks of cardiovascular diseases in conditions of rheumatoid arthritis
- PMID: 31906689
Lipid profile and risks of cardiovascular diseases in conditions of rheumatoid arthritis
Abstract
Cardiovascular diseases (CVD) belong to the leading causes of mortality worldwide. Elevated levels of total cholesterol and LDL cholesterol are associated with increased incidence of CVD in the population. Reversely, reduction of lipoprotein levels in plasma results in a positive impact on CVD prevention. Patients with rheumatoid arthritis (RA), a chronic inflammatory disease, have markedly increased mortality risk due to CVD, despite lower lipoprotein levels in comparison with common population. This is known as the “lipid paradox”. RA itself represents an independent CVD risk factor acting as an inflammatory component. Inflammation, manifested by systemic elevated concentrations of pro-inflammatory cytokines, mainly interleukin 6 (IL-6), interleukin 1β (IL-1β) and the tumour necrosis factor α (TNF-α) in RA, is considered to be the main contributor of atherogenesis via its impact on lipoprotein metabolism and on the biology of the arterial wall. Atherosclerosis, a complex process including a number of mechanisms, is not only regarded as dysregulation of lipid metabolism, but also as a chronic inflammatory disease. This review summarizes the newest findings about the qualitative and quantitative alterations of lipids and lipoproteins affected by low-grade inflammation triggered by RA and their consequences on atherosclerosis.
Keywords: HDL; atherosclerosis; inflammation; lipid metabolism; rheumatoid arthritis.
Similar articles
-
Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease.Ann Rheum Dis. 2011 Mar;70(3):482-7. doi: 10.1136/ard.2010.135871. Epub 2011 Jan 7. Ann Rheum Dis. 2011. PMID: 21216812 Free PMC article.
-
Dyslipidemia in rheumatoid arthritis: the possible mechanisms.Front Immunol. 2023 Oct 25;14:1254753. doi: 10.3389/fimmu.2023.1254753. eCollection 2023. Front Immunol. 2023. PMID: 37954591 Free PMC article. Review.
-
[Lipid profile and cardiovascular risk in patients with rheumatoid arthritis: Effect of the disease and of drug therapy].Ann Endocrinol (Paris). 2010 Sep;71(4):257-63. doi: 10.1016/j.ando.2010.03.005. Epub 2010 Apr 22. Ann Endocrinol (Paris). 2010. PMID: 20416859 Review. French.
-
The Lipid Paradox as a Metabolic Checkpoint and Its Therapeutic Significance in Ameliorating the Associated Cardiovascular Risks in Rheumatoid Arthritis Patients.Int J Mol Sci. 2020 Dec 14;21(24):9505. doi: 10.3390/ijms21249505. Int J Mol Sci. 2020. PMID: 33327502 Free PMC article. Review.
-
Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis.Ann Rheum Dis. 2016 Oct;75(10):1806-12. doi: 10.1136/annrheumdis-2015-207872. Epub 2015 Nov 27. Ann Rheum Dis. 2016. PMID: 26613768 Free PMC article. Clinical Trial.
Cited by
-
Decreased low-density lipoprotein and the presence of pulmonary arterial hypertension among newly diagnosed drug-naïve patients with systemic lupus erythematosus: D-dimer as a mediator.Exp Ther Med. 2022 Jul 27;24(3):595. doi: 10.3892/etm.2022.11531. eCollection 2022 Sep. Exp Ther Med. 2022. PMID: 35949327 Free PMC article.
-
Alterations of HDL's to piHDL's Proteome in Patients with Chronic Inflammatory Diseases, and HDL-Targeted Therapies.Pharmaceuticals (Basel). 2022 Oct 18;15(10):1278. doi: 10.3390/ph15101278. Pharmaceuticals (Basel). 2022. PMID: 36297390 Free PMC article. Review.
-
Lipid metabolism and rheumatoid arthritis.Front Immunol. 2023 May 31;14:1190607. doi: 10.3389/fimmu.2023.1190607. eCollection 2023. Front Immunol. 2023. PMID: 37325667 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical